CORE MOLDING TECHNOLOGIES INC
CMTAbout the company
Core Molding Technologies, Inc., together with its subsidiaries, operates as a molder of thermoplastic and thermoset structural products in the United States, Mexico, Canada, and internationally. The company offers a range of manufacturing processes, such as sheet molding compound compression molding, direct long fiber thermoplastic compression molding, vacuum resin transfer compression molding, structural foam and web injection molding, reaction injection molding, hand lay-up, and spray-up processes.
Investment snapshot
Positive
4
BUY / PASS
Neutral / negative
6 / 6
NEUTRAL / FAIL
Median fair value
$14.80
-33.2% vs price
Models with upside
3 / 17
Positive margin of safety
Strongest signal
All 12 investors pass CMT's debt & leverage
Key risk
14 of 16 flag CMT's profitability — Graham, Buffett, Lynch +11 more
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | NEUTRAL | PASS | FAIL | FAIL · Rank #1548 (Top 50%) | NEUTRAL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL | FAIL | PASS | PASS | BUY | FAIL | NEUTRAL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | |||||||||||
| Margin of Safety | +3.5% | -90.1% | -204.1% | -27.5% | N/A | +13.2% | -855.6% | -49.8% | +40.9% | -105.5% | -1118.1% | -8.4% | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-10 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-10 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-10 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 |
Where It Passes
- Debt & Leverage100% pass✓ 15▾
All 12 investors pass CMT's debt & leverage
LT Debt vs Net Current AssetsLT Debt $0.0M vs NCA $45.0M✓GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.00, IC: 49.1x✓BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0✓Lynch< 0.33Cash - Long-term Debt$5.4M✓LynchPositive preferredLT Debt / Total Assets Change9.40% -> 7.73%✓PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.86✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=49.1x, D/EBITDA=0.0x✓MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)✓AsnessTop 30% of eligible cross-section
Where It Falls Short
- Profitability13% pass✓ 11✗ 24▾
14 of 16 flag CMT's profitability — Graham, Buffett, Lynch +11 more
Positive EPS (10 years)19/24 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)227.6%✓Graham>= 33% growthNet Income Positive (10+ years)21/24 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)9.2%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)5.2% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy$6.3M✓BuffettPositive and growingEarnings Variance (10-yr CoV)1.03✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)3.04✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR5.7%✓Lynch15-30% (Fast Grower); > 0% to passROE4.3%✗Lynch> 15%EBIT / Enterprise Value4.5%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=4.5%, ROC=6.0%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets4.91%✓PiotroskiROA > 0ROA Change YoY6.35% -> 4.91% (delta: -1.44%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=8.41%, ROA=4.91%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY17.6% -> 17.4%✗PiotroskiImproved YoYPre-Tax Income / Revenue3.0%✗Dreman>= 8%Net Income / Shareholders' Equity4.3%✗Dreman> 12%Margin of SafetyP/E=17.2x, P/B=1.2x✓PabraiP/B < 1.5 or P/E < 15Return on Equity10.2% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value13.2% (IV=$25.55 vs Price=$22.17)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency21/23 years positive✓MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue2.9%✗Ackman>= 15%Net Income / Shareholders Equity4.3%✗Ackman>= 15%5-Year EPS CAGR5.7% CAGR over 5 years✓Templeton> 0% (5-year EPS CAGR)Operating Margin Trend7.4% (2023) -> 5.2% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 18.0% -> 17.4%, operating margin 7.4% -> 5.2%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization+3.68%; #2144/6340 (top 33.8%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+21.40%; #1967/3702 (top 53.1%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity+4.33%; #2534/5226 (top 48.5%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.0228; #1592/5884 (top 27.1%)✓AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR5.7% over 5 years✗Neff7%-20% annualizedPositive Diluted-EPS Years8/10 years positive✓Schloss>= 70% positive over 5-10 observed years (app rule) - Valuation15% pass✓ 8✗ 20▾
11 of 13 flag CMT's valuation — Lynch, Greenblatt, Dreman +8 more
Price / Book Value per Share1.2x✗Dreman< 1.2x✓Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Price / 3-yr avg EPS13.0x✓Graham<= 15xPrice-to-Book Ratio1.2x✓Graham<= 1.5xP/E x P/B15.90✓Graham<= 22.5Basic earnings-growth PEG (dividends excluded)3.04✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value4.5%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=4.5%, ROC=6.0%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS17.2x✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)10.1x✗Dreman< 8xValuation ReasonablenessP/E=17.2x, OE Yield=3.3%✓MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldP/E=17.2x, FCF Yield=1.0%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/E=17.2x, P/B=1.2x✓MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value13.2% (IV=$25.55 vs Price=$22.17)✗Marks>= 20% below intrinsic valuePrice / FCF per Share100.6x✗Ackman<= 25Price vs. Trailing Low161% of trailing low ($13.73)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization+3.68%; #2144/6340 (top 33.8%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.8497; #1803/6449 (top 28.0%)✓AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS17.2x✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share1.40x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change+54.5%✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+1.5091; #1328/5247 (top 25.3%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-10.16%; #3239/4519 (top 71.7%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-6.89%; #3243/6202 (top 52.3%)✗OshaughnessyTop 10% of eligible cross-section - Efficiency25% pass✓ 4✗ 7▾
6 of 8 flag CMT's efficiency — Graham, Greenblatt, Piotroski +3 more
Current Ratio1.86✗Graham>= 2.0ROIC (3-5 yr avg)10.3%✓Buffett> 10%ROIC - WACC+0.3%✓BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)6.0%✗Greenblatt> 25%Current Ratio Change YoY2.80 -> 3.02✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY1.44x -> 1.20x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities1.86✓Dreman> 1.5Return on Invested Capital4.0%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=12.9%; FY2024: ROIC=7.8%; FY2025: ROIC=6.3%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC6.3% (RR=100% x ROIC=6.3%)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)1/5 years above 12% (latest 6.3%)✗SleepROIC > 12% in a majority of years - Valuation models27% pass✓ 3✗ 8▾
Models split on CMT at $22.17 — fair values range $1.82–$37.52
Graham fair value$22.97✓Graham+3.5% margin vs $22.17Buffett fair value$11.66✗Buffett-90.1% margin vs $22.17Lynch fair value$7.29✗Lynch-204.1% margin vs $22.17Greenblatt fair value$17.39✗Greenblatt-27.5% margin vs $22.17Dreman fair value$25.55✓Dreman+13.2% margin vs $22.17Munger fair value$2.32✗Munger-855.6% margin vs $22.17Pabrai fair value$14.80✗Pabrai-49.8% margin vs $22.17Akre fair value$37.52✓Akre+40.9% margin vs $22.17Marks fair value$10.79✗Marks-105.5% margin vs $22.17Ackman fair value$1.82✗Ackman-1118.1% margin vs $22.17Templeton fair value$20.45✗Templeton-8.4% margin vs $22.17 - Verdicts36% pass✓ 4✗ 7▾
Split decision: 6 NEUTRAL · 6 FAIL · 3 PASS · 1 BUY
Overall verdict•GrahamNEUTRAL (6/9)✓BuffettPASS (5/9)✗LynchFAIL (3/7)✗GreenblattRank #1548•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (3/11)•MungerNEUTRAL (3/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)•MarksNEUTRAL (4/5)✗AckmanFAIL (2/9)✓TempletonPASS (4/8)✓SleepPASS (3/6)✓AsnessBUY (Rank #118/2370 (Top 5.0%))✗NeffFAIL (1/6)•SchlossNEUTRAL (4/7)•OshaughnessyNEUTRAL (Not ranked) - Growth38% pass✓ 5✗ 8▾
5 of 8 flag CMT's growth — Lynch, Dreman, Ackman +2 more
EPS Growth (3-yr avg, 10-yr window)227.6%✓Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)3.04✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR5.7%✓Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: 34.8% vs Rev: 9.4%✗LynchInventory growth < Revenue growthEPS Growth Direction$0.52 (2004) -> $1.29 (2025)✓DremanPositive over recent yearsEPS CAGR4.4% CAGR over 21 years✗Dreman> 5% annualizedPositive Net Income Frequency21/23 years positive✓MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-9.5%✗Ackman>= 5%Positive EPS Growth Frequency2/5 years with positive EPS growth✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR5.7% CAGR over 5 years✓Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 18.0% -> 17.4%, operating margin 7.4% -> 5.2%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR4.3%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR5.7% over 5 years✗Neff7%-20% annualized - Cash Flow40% pass✓ 5✗ 7▾
6 of 10 flag CMT's cash flow — Lynch, Dreman, Pabrai +3 more
Free Cash Flow Proxy$6.3M✓BuffettPositive and growingFCF Positive and Growing$-19.3M✗LynchPositive and growingOperating Cash Flow$19.2M✓PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=8.41%, ROA=4.91%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)10.1x✗Dreman< 8xP/E or FCF YieldP/E=17.2x, FCF Yield=1.0%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive14/16 years FCF positive✓MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-10.0%✗Ackman>= 4%Price / FCF per Share100.6x✗Ackman<= 25Positive Operating Cash Flow frequency20/21 years positive✓SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-19.3M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-10.16%; #3239/4519 (top 71.7%)✗OshaughnessyTop 10% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Retired 1.0% of shares last year, 0.5% issued over two.
- Buybacks
- $3.2M
- Dividends
- —
What drove EPS
A buyback raises earnings per share without the company earning more. This splits each year's change into the two.
The two parts do not sum exactly to the total — the difference is the cross-term, plus preferred capital where the company has any. It is left visible rather than distributed into the other two.
Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex, buybacks. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $189.7Mcurrent | -- | -- | -- | $169.8Mest. | $129.8Mest. | $149.7Mest. | $131.3Mest. | $66.0Mest. |
| Revenue | $286.2M↑9% | $90.2M↑54% | $62.7M↓21% | $58.6M↓5% | $273.8M↓9% | $302.4M↓15% | $357.7M↓5% | $377.4M↑23% | $307.5M |
| Operating Income | $8.2M↓28% | $1.6M↓38% | $2.3M↓56% | $764.0K↓73% | $14.2M↓15% | $16.7M↓37% | $26.5M↑47% | $18.0M↑63% | $11.1M |
| Net Income | $7.0M↓13% | $1.5M↓19% | $1.8M↓56% | $605.0K↓72% | $11.2M↓16% | $13.3M↓35% | $20.3M↑67% | $12.2M↑161% | $4.7M |
| EPS (Diluted) | -- | $0.17↓23% | $0.21↓55% | $0.07↓72% | $1.29↓15% | $1.51↓35% | $2.31↑60% | $1.44↑162% | $0.55 |
| Gross Margin | 17.3%↓2% | 14.8%↓15% | 20.3%↑12% | 20.4%↑7% | 17.4%↓1% | 17.6%↓2% | 18.0%↑30% | 13.9%↑3% | 13.4% |
| Operating Margin | 2.9%↓34% | 1.8%↓60% | 3.7%↓44% | 1.3%↓72% | 5.2%↓6% | 5.5%↓26% | 7.4%↑55% | 4.8%↑33% | 3.6% |
| ROE | 4.3%↓17% | — | — | — | 7.1%↓22% | 9.0%↓38% | 14.6%↑39% | 10.5%↑125% | 4.7% |
| Total Debt | $0↓100% | $0↓100% | $0↓100% | $19.3M↓9% | $19.7M↓8% | $21.5M↓6% | $23.0M↓5% | $24.2M↓4% | $25.2M |
| Shareholders' Equity | $161.1M↑4% | $161.1M↑4% | $161.1M↑5% | $158.2M↑6% | $158.2M↑7% | $147.4M↑6% | $139.0M↑20% | $116.1M↑16% | $100.1M |
| Current Ratio | 1.86↓36% | 1.86↓36% | 2.00↓30% | 2.41↓3% | 3.02↑8% | 2.80↑26% | 2.23↑40% | 1.59↑12% | 1.42 |
| Debt / Equity | 0.00↓100% | 0.00↓100% | 0.00↓100% | 0.12↓13% | 0.12↓15% | 0.15↓12% | 0.17↓21% | 0.21↓17% | 0.25 |
| Operating Cash Flow | $8.4M↓56% | -$3.7M↓181% | $16.3M↑366% | -$9.2M↓251% | $19.2M↓45% | $35.2M↑1% | $34.8M↑84% | $19.0M↑51% | $12.5M |
| Free Cash Flow | -$19.3M↓459% | -$11.3M↓3171% | $8.0M↑809% | -$13.0M↓401% | $1.9M↓92% | $23.6M↓8% | $25.7M↑975% | $2.4M↑145% | $977.0K |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Rubber and Plastic Products
CMT vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENTEGRIS INCENTG | $22.5B | $147.41 | $3.2B | $235.6M | 6.0% | 0.94 | 14.3% | 3.35 | 2/9 | 2/9 | 1/7 | 1/3 | F-Score 5 | 4/11 |
| CARLISLE COMPANIES INCCSL | $15.3B | $396.13 | $5.0B | $740.7M | 41.3% | 1.61 | 20.0% | 3.09 | 4/9 | 6/9 | 3/7 | 1/3 | F-Score 5 | 4/11 |
| ADVANCED DRAINAGE SYSTEMS, INC.WMS | $9.3B | $125.58 | $3.1B | $426.5M | 22.9% | 0.87 | 20.3% | 2.42 | 2/9 | 5/9 | 3/7 | 1/3 | F-Score 4 | 4/11 |
| APTARGROUP, INC.ATR | $9.1B | $143.09 | $3.8B | $392.8M | 14.7% | 0.49 | 13.3% | 1.62 | 2/9 | 6/9 | 2/7 | 1/3 | F-Score 6 | 6/11 |
| ARMSTRONG WORLD INDUSTRIES INCAWI | $7.4B | $175.74 | $1.6B | $308.7M | 34.3% | 0.45 | 26.6% | 1.46 | 1/9 | 5/9 | 2/7 | 1/3 | F-Score 9 | 6/11 |
| Enpro Inc.NPO | $5.8B | $273.63 | $1.1B | $40.5M | 2.6% | 0.42 | 14.1% | 2.32 | 2/9 | 2/9 | 2/7 | 1/3 | F-Score 6 | 3/11 |
| NEWELL BRANDS INC.NWL | $2.5B | $5.78 | $7.2B | $285.0M | -11.9% | 1.95 | 0.5% | 1.07 | 3/9 | 0/9 | 1/7 | 0/3 | F-Score 3 | 3/11 |
| MYERS INDUSTRIES INCMYE | $1.1B | $28.07 | $825.7M | $34.9M | 11.9% | 1.18 | 9.0% | 1.67 | 2/9 | 4/9 | 2/7 | 1/3 | F-Score 6 | 3/11 |